Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-11
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 261
- Registration Number
- NCT04194944
- Locations
- 🇨🇳
The First Affiated Hospital Of Guangzhou Medical Collage, Guangzhou, Guangzhou, China
🇦🇷Alexander Fleming, Ciudad de Buenos Aires, Argentina
🇨🇳Buddhist Dalin Tzu Chi General Hospital, Dalin Town, Chiayi, Taiwan
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Augusta University
- Target Recruit Count
- 9
- Registration Number
- NCT04173338
- Locations
- 🇺🇸
Augusta University Georgia Cancer Center, Augusta, Georgia, United States
Plasma-Adapted First-Line Pembro in NSCLC
- Conditions
- Interventions
- First Posted Date
- 2019-11-18
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Julia K. Rotow, MD
- Target Recruit Count
- 40
- Registration Number
- NCT04166487
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber at Steward St. Elizabeth's Medical Center, Brighton, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 450
- Registration Number
- NCT04165070
- Locations
- 🇺🇸
Cleveland Clinic Main ( Site 0006), Cleveland, Ohio, United States
🇺🇸The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus, Ohio, United States
🇺🇸Abramson Cancer Center of the University of Pennsylvania ( Site 0010), Philadelphia, Pennsylvania, United States
Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC
- Conditions
- Interventions
- First Posted Date
- 2019-11-14
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 84
- Registration Number
- NCT04163432
- Locations
- 🇺🇸
Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2019-11-13
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT04162015
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering Nassau, Uniondale, New York, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 16
- Registration Number
- NCT04158141
- Locations
- 🇨🇦
The Research Institute of the McGill University Health Centre (MUHC), Montreal, Quebec, Canada
🇺🇸Moffitt Cancer Center - McKinley Campus, Tampa, Florida, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC
- First Posted Date
- 2019-11-06
- Last Posted Date
- 2019-11-06
- Lead Sponsor
- Kobe Minimally Invasive Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT04153734
A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)
- Conditions
- Interventions
- First Posted Date
- 2019-11-06
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 19
- Registration Number
- NCT04153565
- Locations
- 🇯🇵
Kanagawa Cancer Center ( Site 0004), Yokohama, Kanagawa, Japan
🇯🇵JOHAS Okayama Rosai Hospital ( Site 0002), Okayama, Japan
🇯🇵Hyogo College of Medicine Hospital ( Site 0003), Nishinomiya, Hyogo, Japan
Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 105
- Registration Number
- NCT04136535
- Locations
- 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.